UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
| | | |
| Date of Report (Date of Earliest Event Reported): | | July 7, 2005 |
Anadys Pharmaceuticals, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)
| | | |
| Delaware | 000-50632 | 22-3193172 |
_____________________
(State or other jurisdiction | _____________
(Commission | ______________
(I.R.S. Employer |
| of incorporation) | File Number) | Identification No.) |
| | | |
| 3115 Merryfield Row, San Diego, California | | 92121 |
_________________________________
(Address of principal executive offices) | | ___________
(Zip Code) |
| | | |
| Registrant’s telephone number, including area code: | | (858) 530-3600 |
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On July 7, 2005, Anadys Pharmaceuticals, Inc. announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act with respect to the License and Co-Development Agreement entered into on June 1, 2005 with Novartis International Pharmaceutical Ltd., a Novartis AG Company. As a result of the expiration of the waiting period, the License and Co-Development Agreement became effective on July 7, 2005.
A copy of the Company's press release describing this event is filed herewith and attached as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
(c) Exhibits
99.1 Press Release of Anadys Pharmaceuticals, Inc. dated July 7, 2005.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
| | | Anadys Pharmaceuticals, Inc. |
| | | | | |
| July 7, 2005 | | By: | | /s/ Jennifer K. Crittenden
|
| | | | |
|
| | | | | Name: Jennifer K. Crittenden |
| | | | | Title: Vice President Finance |
Exhibit Index
| | | |
| Exhibit No. | | Description |
| |
|
99.1 | | Press Release of Anadys Pharmaceuticals, Inc. dated July 7, 2005 |
